List of Vyzulta drug patents

Vyzulta is owned by Bausch And Lomb.

Vyzulta contains Latanoprostene Bunod.

Vyzulta has a total of 4 drug patents out of which 0 drug patents have expired.

Vyzulta was authorised for market use on 02 November, 2017.

Vyzulta is available in solution/drops;ophthalmic dosage forms.

Vyzulta can be used as reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension.

The generics of Vyzulta are possible to be released after 03 October, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058467 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 11 months from now)

US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 11 months from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 11 months from now)

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of VYZULTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in